Feedback on the September 2024 PRAC (2–5 September)

News Consumer protection French Guidance

Date: 13th Sep, 2024 Source: The National Agency for the Safety of Medicines and Health Products Country: France Original Source

Brief

Le comité de pharmacovigilance (PRAC) de l’Agence européenne des médicaments (EMA) recommande de nouvelles mesures pour réduire le risque de méningiome associé aux médicaments à base d’acétate de médroxyprogestérone à fortes doses (oral et injectable ≥ 100 mg). Le PRAC alerte les professionnels de santé sur l’interprétation des tests de phénotypage du déficit en dihydropyrimidine

Hello!

To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.

Go to Home Page

Highlights content goes here...

Hello!

To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.

Go to Home Page

The National Agency for the Safety of Medicines and Health Products

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

Feedback on the September 2024 PRAC (2–5 September)

Brief

The National Agency for the Safety of Medicines and Health Products

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

Feedback on the September 2024 PRAC (2–5 September)

Brief

The National Agency for the Safety of Medicines and Health Products

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.